Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02677116
Title A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

Advanced Solid Tumor

central nervous system cancer

Therapies

Doxorubicin

Ifosfamide

Irinotecan + Vincristine Sulfate

Olaratumab

Age Groups: child
Covered Countries USA


No variant requirements are available.